Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

That’s gene editing. On paper, it is merely the rearrangement of letters. However, the road to editing genes in hopes of a therapeutic benefit is difficult to travel. Additionally, researchers want ...

Lentiviral vectors remain a cornerstone in cell and gene therapy applications, offering high transduction efficiency and integration capability. However, achieving consistent recovery during ...

SHANGHAI, May 15, 2025 /PRNewswire/ -- Immunofoco, a company dedicated to advancing cell therapies for solid tumors, announced that its independently developed, innovative lentiviral vector-based In ...

MARTINSRIED, Germany--(BUSINESS WIRE)--SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products. CAR-T cell ...

MUNICH & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer ...

Despite the recent attention to the potential of developing and using gene therapy to treat several diseases, the therapy was ...